The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a ...

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market ...

The U.S. Food and Drug Administration on Wednesday approved a second oral GLP-1 medication, giving adults eligible for weight ...

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

Add Yahoo as a preferred source to see more of our stories on Google. Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One ...

As open enrollment launches at the Group Insurance Commission Wednesday, thousands of state employees and retirees will no ...

Use of obesity drugs has become widespread, but not necessarily in the right patients ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Eli Lilly and Company LLY shares gained 3.8% on Wednesday after the company announced the FDA approval of its oral GLP-1 drug, orforglipron, for adults with obesity or overweight with weight-related ...

This Study explores several new DehydraTECH enhancements not previously evaluated, which include but are not limited to the ...

The GLP-1 wave has triggered a broader biopharma M&A cycle, and these five biotech companies represent compelling acquisition ...

Foundayo, a once-daily oral GLP-1 medication approved for obesity and weight-related issues, ranges in cost from $25 to $349 ...